Table 5 The trough concentrations of 116-N1 at day 5 and day 6 in multiple ascending-dose study.

From: Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects

Concentration (ng/mL)

200 mg (n = 9)

400 mg (n = 9)

600 mg (n = 9)

Pre-dose of 1st dosing at day 5

345 (88.2)

766 (310)

1011 (311)

Pre-dose of 2nd dosing at day 5

242 (56.9)

559 (242)

721 (272)

Pre-dose at day 6

326 (75.7)

669 (262)

924 (277)

  1. Note: Data are expressed as mean (SD).
Back to article page